AAAAI Disclosure Policy

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:

Employment. Name of employer and job title.

Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).

Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.

Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.

Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.

Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.

Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.

Faculty

William W. Busse, MD

Professor of Medicine
Division of Allergy and Pulmonology and Critical Care Medicine
University of Wisconsin
School of Medicine and Public Health
Madison, Wisconsin

Disclosures

Disclosure: William W. Busse, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; ResTORbio Inc.; Sanofi; TEVA PHARMACEUTICALS USA
Other: Boston Scientific; Genentech, Inc.

Stephen Peters, MD, PhD

Davis Professor and Chief
Section on Pulmonary, Critical Care, Allergy, & Immunologic Diseases
Wake Forest School of Medicine
Wake Forest Baptist Health
Winston-Salem, North Carolina

Disclosures

Disclosure: Stephen Peters, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.; GlaxoSmithKline; Mylan Laboratories Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi; TEVA PHARMACEUTICALS USA; Theravance

Editor

Roderick Smith, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

Kevin Parks, MD FAAAAI
AAC/CRI of Southern Oregon, Medford, OR
Relevant relationships: None

CME

Foundations of Asthma: Expanding the Role of Biomarkers in Managing Therapy

Authors: William W. Busse, MD; Stephen Peters, MD, PhD
CME Released: 9/19/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/19/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for allergists & clinical immunologists, pulmonologists, and primary care physicians.

The goal of this activity is to increase clinicians' knowledge regarding the availability and appropriate use of biomarkers to assess asthma severity and select treatments.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Common biomarkers employed in the management of patients with asthma
- Role of allergists in a biomarker-based approach to managing patients with asthma

Disclosures

AAAAI Disclosure Policy

Employment. Name of employer and job title.

Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).

Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.

Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.

Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.

Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.

Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

Faculty

William W. Busse, MD

Professor of Medicine
Division of Allergy and Pulmonology and Critical Care Medicine
University of Wisconsin
School of Medicine and Public Health
Madison, Wisconsin

Disclosures

Disclosure: William W. Busse, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; ResTORbio Inc.; Sanofi; TEVA PHARMACEUTICALS USA
Other: Boston Scientific; Genentech, Inc.

Stephen Peters, MD, PhD

Davis Professor and Chief
Section on Pulmonary, Critical Care, Allergy, & Immunologic Diseases
Wake Forest School of Medicine
Wake Forest Baptist Health
Winston-Salem, North Carolina

Disclosures

Disclosure: Stephen Peters, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.; GlaxoSmithKline; Mylan Laboratories Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi; TEVA PHARMACEUTICALS USA; Theravance

Editor

Roderick Smith, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

Content Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

Kevin Parks, MD FAAAAI
AAC/CRI of Southern Oregon, Medford, OR
Relevant relationships: None

Accreditation Statements

AAAAI Privacy Policy

To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at [email protected]

For Physicians

The AAAAI is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact this provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Allergy & Clinical Immunology

CME

Foundations of Asthma: Expanding the Role of Biomarkers in Managing Therapy

Authors: William W. Busse, MD; Stephen Peters, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 9/19/2019

Valid for credit through: 9/19/2020

processing....

Abbreviations

anti-IL-4R = anti-IL-4 receptor α chain
anti-IL-5R = anti-IL-5 receptor α chain
CS = corticosteroid
ED = emergency department
FeNO = fractional exhaled nitric oxide
ICS = inhaled corticosteroid
Ig = immunoglobulin
IL = interleukin
LABA = long-acting beta agonist
LAMA = long-acting muscarinic antagonist
mAb = monoclonal antibody
T2 = type 2

« Return to: Foundations of Asthma: Expanding the Role of Biomarkers in Managing Therapy